JP7185401B2 - 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 - Google Patents

嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 Download PDF

Info

Publication number
JP7185401B2
JP7185401B2 JP2017557954A JP2017557954A JP7185401B2 JP 7185401 B2 JP7185401 B2 JP 7185401B2 JP 2017557954 A JP2017557954 A JP 2017557954A JP 2017557954 A JP2017557954 A JP 2017557954A JP 7185401 B2 JP7185401 B2 JP 7185401B2
Authority
JP
Japan
Prior art keywords
antibody
tissue
formulation
delivery
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520995A5 (enExample
JP2018520995A (ja
Inventor
ミル イムラン，
ラディカ コルポル，
エレイン トー，
ミル ハシム，
Original Assignee
ラニ セラピューティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラニ セラピューティクス， エルエルシー filed Critical ラニ セラピューティクス， エルエルシー
Publication of JP2018520995A publication Critical patent/JP2018520995A/ja
Publication of JP2018520995A5 publication Critical patent/JP2018520995A5/ja
Application granted granted Critical
Publication of JP7185401B2 publication Critical patent/JP7185401B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017557954A 2015-05-08 2016-05-09 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 Active JP7185401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
US62/159,134 2015-05-08
PCT/US2016/031548 WO2016183040A1 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020196688A Division JP7232805B2 (ja) 2015-05-08 2020-11-27 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤

Publications (3)

Publication Number Publication Date
JP2018520995A JP2018520995A (ja) 2018-08-02
JP2018520995A5 JP2018520995A5 (enExample) 2019-06-13
JP7185401B2 true JP7185401B2 (ja) 2022-12-07

Family

ID=57248408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017557954A Active JP7185401B2 (ja) 2015-05-08 2016-05-09 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤
JP2020196688A Active JP7232805B2 (ja) 2015-05-08 2020-11-27 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020196688A Active JP7232805B2 (ja) 2015-05-08 2020-11-27 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤

Country Status (6)

Country Link
EP (1) EP3294273A4 (enExample)
JP (2) JP7185401B2 (enExample)
CN (1) CN107835682A (enExample)
AU (2) AU2016261599B2 (enExample)
CA (1) CA2984422C (enExample)
WO (1) WO2016183040A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
CN108401419A (zh) * 2015-09-08 2018-08-14 因库博实验室有限责任公司 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂
WO2018112256A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
BR112021012959A2 (pt) * 2018-12-31 2021-09-08 Rani Therapeutics, Llc Preparações de agente terapêutico para a liberação em um lúmen do trato intestinal pela utilização de um dispositivo de liberação de fármaco engolível
EP4188508A2 (en) * 2020-07-30 2023-06-07 Verily Life Sciences LLC Pill with needle delivery system having outwardly expanding mechanical actuation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515576A (ja) 2009-12-24 2013-05-09 インキューブ ラブズ， エルエルシー 嚥下可能薬物送達デバイスおよび薬物送達方法
JP2014520812A (ja) 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
JP2014520600A (ja) 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 治療用化合物の経口送達のためのデバイス、システム、および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
JP2010502759A (ja) * 2006-09-12 2010-01-28 コスモ・テクノロジーズ・リミテツド タンパク質物質の経口または直腸投与のための医薬組成物
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
US8562589B2 (en) * 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
AU2013334740A1 (en) * 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
CN107072955B (zh) * 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
CN113546036A (zh) * 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515576A (ja) 2009-12-24 2013-05-09 インキューブ ラブズ， エルエルシー 嚥下可能薬物送達デバイスおよび薬物送達方法
JP2014520812A (ja) 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
JP2014520600A (ja) 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 治療用化合物の経口送達のためのデバイス、システム、および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎｉｃａｌ， Ｃｏｓｍｅｔｉｃ ａｎｄ Ｉｎｖｅｓｔｉｇａｔｉｏｎａｌ Ｄｅｒｍａｔｏｌｏｇｙ，２０１４年，Ｖｏｌ．７，ｐ．２５１－２５９
生化学，２０１１年，Ｖｏｌ．８３， Ｎｏ．１，ｐ．１３－２２

Also Published As

Publication number Publication date
EP3294273A4 (en) 2018-12-05
CA2984422A1 (en) 2016-11-17
AU2016261599A1 (en) 2017-11-23
JP2021042239A (ja) 2021-03-18
CA2984422C (en) 2023-10-17
AU2021269453A1 (en) 2021-12-16
EP3294273A1 (en) 2018-03-21
WO2016183040A1 (en) 2016-11-17
CN107835682A (zh) 2018-03-23
AU2016261599B2 (en) 2021-08-26
JP2018520995A (ja) 2018-08-02
JP7232805B2 (ja) 2023-03-03
AU2021269453B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP7305008B2 (ja) 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
US20230174639A1 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7232805B2 (ja) 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤
US11771879B2 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20240109959A1 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10300010B2 (en) Methods for delivering entanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
JP2023104992A (ja) 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210402

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210405

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210430

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210902

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20211007

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220510

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220628

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20220902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221004

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221101

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221125

R150 Certificate of patent or registration of utility model

Ref document number: 7185401

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250